NOW ENROLLING PHASE III sunRIZE TRIAL In the study of congenital hyperinsulinism

Learn More »
sunrize logo

Imagine a world

where days
are defined by
special moments

and balance is restored
to the lives of patients
and their families.

Disease Focus

Congenital hyperinsulinism (CHI) is a rare genetic disease that presents very early in life and is characterized by excess and erratic insulin secretion that can cause infants, children, and adults to become dangerously hypoglycemic and starve their bodies of glucose.

Diabetic Macular Edema (DME) is a disease associated with diabetes, when chronic excess glucose in the blood stream can cause inflammation and breakdown of the body’s blood vessels, including at the back of the eye where fluid may leak into the retina. DME is the leading cause of blindness in the US and elsewhere.

Tumor-associated hyperinsulinism (taHI) occurs when pancreatic neuroendocrine tumors (i.e. “insulinomas”) over-produce insulin, resulting in excessive insulin receptor activation and hypoglycemia. Insulinomas are the most common type of functional pancreatic neuroendocrine tumor, affecting 10,000-15,000 patients in the US, of which ~10 percent have malignant/unresectable tumors requiring chronic medical therapies to directly to control their hypoglycemia.

Our Story

At REZOLUTE, we are driven to develop novel therapies that boldly transform the treatment paradigm for debilitating diseases with significant unmet needs. We listen to the patient and the community to guide and inform our approach on bringing forward therapeutics that can make a difference. As parents, patients, and caregivers, the spectrum of our humanity informs and inspires everything we do in our mission to develop life-changing therapies. We are REZOLUTE in our commitment to restore balance to life.

Our Vision

A world where days are defined by special moments and balance is restored to the lives of patients and their families.